Opioid Education Program

Pain management has become a challenging field both for the patients, their families, and providers. The rise of the opioid crisis has made the availability of opioids limited, even for those patients who truly need the life changing medications. Nurses, physicians, and administrators play a vital role in patient education and the education regarding the importance of using opioids safely. Lack of patient education regarding the use, misuse, and side effects of opioids can lead to potential injuries, overdose, and even death. Providing patients with an educational program would greatly decrease their risk of misuse and abuse of opioids. During the educational program, information regarding the potentially dangerous medications they are prescribed would be discussed as well as information regarding how to identify overdose signs, symptoms, and what to do in case of overdose. Furthermore, patients would have the opportunity to ask questions they would have otherwise not asked in the clinical setting. This would result in higher compliance, safer consumption, and increase in knowledge regarding the opioid medications which would mitigate the patient\u27s risk, decrease the nurses risk, and the risk to the organization. Effectiveness would be determined by written pre and post-tests provided to patients during the program. Additionally, this data would be collected and weighed against cost, time spent on the project, and patient knowledge to determine if sustainability is appropriate

A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly

Objective: ATL1103 is a second-generation antisense oligomer targeting the human growth hormone (GH) receptor. This phase 2 randomised, open-label, parallel-group study assessed the potential of ATL1103 as a treatment for acromegaly. Design: Twenty-six patients with active acromegaly (IGF-I >130% upper limit of normal) were randomised to subcutaneous ATL1103 200mg either once or twice weekly for 13 weeks and monitored for a further 8-week washout period. Methods: The primary efficacy measures were change in IGF-I at week 14, compared to baseline and between cohorts. For secondary endpoints (IGFBP3, acid labile subunit (ALS), GH, growth hormone-binding protein (GHBP)), comparison was between baseline and week 14. Safety was assessed by reported adverse events. Results and conclusions: Baseline median IGF-I was 447 and 649 ng/mL in the once- and twice-weekly groups respectively. Compared to baseline, at week 14, twice-weekly ATL1103 resulted in a median fall in IGF-I of 27.8% (P = 0.0002). Between cohort comparison at week 14 demonstrated the median fall in IGF-I to be 25.8% (P = 0.0012) greater with twice-weekly dosing. In the twice-weekly cohort, IGF-I was still declining at week 14, and remained lower at week 21 than at baseline by a median of 18.7% (P = 0.0005). Compared to baseline, by week 14, IGFBP3 and ALS had declined by a median of 8.9% (P = 0.027) and 16.7% (P = 0.017) with twice-weekly ATL1103; GH had increased by a median of 46% at week 14 (P = 0.001). IGFBP3, ALS and GH did not change with weekly ATL1103. GHBP fell by a median of 23.6% and 48.8% in the once- and twice-weekly cohorts (P = 0.027 and P = 0.005) respectively. ATL1103 was well tolerated, although 84.6% of patients experienced mild-to-moderate injection-site reactions. This study provides proof of concept that ATL1103 is able to significantly lower IGF-I in patients with acromegaly

Radiocarbon Dating of Ceramic Materials: Progress and Prospects

From the 10th International Radiocarbon Conference held in Bern, Switzerland and Heidelberg, Germany, August 19-26, 1979.Although initial studies in the 1960's established the feasibility of applying the radiocarbon technique directly to ceramics, subsequent analyses have revealed this category of materials to be more complex than previously believed. Consideration of the points at which various types of organic carbon are introduced into ceramic materials by natural or human agencies allows more effective screening of potential sherd samples. It also suggest ways to overcome some of the limiting factors involved in dating ceramics.This material was digitized as part of a cooperative project between Radiocarbon and the University of Arizona Libraries.The Radiocarbon archives are made available by Radiocarbon and the University of Arizona Libraries. Contact [email protected] for further information.Migrated from OJS platform February 202

Olmstead v. L.C.: Implications and Subsequent Judicial, Administrative, and Legislative Actions

This report will discuss the Supreme Court's decision, subsequent lower court decisions, the Health Care Financing Administration (HCFA) letter, and selected legislation

Exploring the limits Frontiers and boundaries in prehistory

10.00SIGLEAvailable from British Library Lending Division - LD:1863.1873(BAR-IS--223) / BLDSC - British Library Document Supply CentreGBUnited Kingdo